CY1107051T1 - Αντι-διηθητικα και αντι-αγγειογενετικα θραυσματα ουροκινασης και η χρηση τους - Google Patents

Αντι-διηθητικα και αντι-αγγειογενετικα θραυσματα ουροκινασης και η χρηση τους

Info

Publication number
CY1107051T1
CY1107051T1 CY20071100065T CY071100065T CY1107051T1 CY 1107051 T1 CY1107051 T1 CY 1107051T1 CY 20071100065 T CY20071100065 T CY 20071100065T CY 071100065 T CY071100065 T CY 071100065T CY 1107051 T1 CY1107051 T1 CY 1107051T1
Authority
CY
Cyprus
Prior art keywords
angiogenesis
pro
glu
ser
variant
Prior art date
Application number
CY20071100065T
Other languages
English (en)
Inventor
Terence R Jones
Andrew P Mazar
Original Assignee
Angstrom Pharmaceuticals, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Angstrom Pharmaceuticals, Inc. filed Critical Angstrom Pharmaceuticals, Inc.
Publication of CY1107051T1 publication Critical patent/CY1107051T1/el

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
    • C12N9/64—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
    • C12N9/6421—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from mammals
    • C12N9/6424—Serine endopeptidases (3.4.21)
    • C12N9/6456—Plasminogen activators
    • C12N9/6462—Plasminogen activators u-Plasminogen activator (3.4.21.73), i.e. urokinase
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
    • C12Y304/21—Serine endopeptidases (3.4.21)
    • C12Y304/21073—Serine endopeptidases (3.4.21) u-Plasminogen activator (3.4.21.73), i.e. urokinase
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Wood Science & Technology (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Biomedical Technology (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Molecular Biology (AREA)
  • Microbiology (AREA)
  • Dermatology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Oncology (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Materials For Medical Uses (AREA)

Abstract

Μια πεπτιδική ένωση η οποία έχει την αλληλουχία Lys-Pro-Ser-Ser-Pro-Pro-Glu-Glu [SEQ ID NO:2] ή μια παραλλαγή υποκατάστασης, παραλλαγή προσθήκης ή άλλο χημικό παράγωγο αυτής αναστέλλει την κυτταρική διήθηση, το σχηματισμό ενδοθηλιακού σωλήνα ή την αγγειογένεση in vitro. Ένας αριθμός παραλλαγών υποκατάστασης και παραλλαγών προσθήκης του πεπτιδίου αυτού, κατά προτίμηση καλυμμένων στα Ν- και C-τελικά άκρα, καθώς επίσης και πεπτιδομιμητικών παραγώγων, είναι χρήσιμος για την αντιμετώπιση νόσων και καταστάσεων οι οποίες διαμεσολαβούνται από ανεπιθύμητη και ανεξέλεγκτη κυτταρική διήθηση και/ή αγγειογένεση. Φαρμακευτικές συνθέσεις οι οποίες περιλαμβάνουν τα παραπάνω πεπτίδια και παράγωγα χορηγούνται σε υποκείμενα τα οποία έχουν ανάγκη μια τέτοια αγωγή σε μια δοσολογία επαρκή ώστε να αναστέλλει την διήθηση και/ή την αγγειογένεση. Οι γνωστοποιούμενες συνθέσεις και μέθοδοι είναι ιδιαίτερα χρήσιμες για την καταστολή της αύξησης και της μετάστασης όγκων.
CY20071100065T 1997-07-25 2007-01-16 Αντι-διηθητικα και αντι-αγγειογενετικα θραυσματα ουροκινασης και η χρηση τους CY1107051T1 (el)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US08/900,327 US5994309A (en) 1997-07-25 1997-07-25 Anti-invasive and anti-angiogenic compositions and methods
EP98937112A EP0950096B1 (en) 1997-07-25 1998-07-24 Anti-invasive and anti-angiogenic urokinase fragments and their use

Publications (1)

Publication Number Publication Date
CY1107051T1 true CY1107051T1 (el) 2012-10-24

Family

ID=25412335

Family Applications (1)

Application Number Title Priority Date Filing Date
CY20071100065T CY1107051T1 (el) 1997-07-25 2007-01-16 Αντι-διηθητικα και αντι-αγγειογενετικα θραυσματα ουροκινασης και η χρηση τους

Country Status (11)

Country Link
US (5) US5994309A (el)
EP (1) EP0950096B1 (el)
AT (1) ATE342967T1 (el)
AU (1) AU752205B2 (el)
CA (1) CA2269772A1 (el)
CY (1) CY1107051T1 (el)
DE (1) DE69836199T2 (el)
DK (1) DK0950096T3 (el)
ES (1) ES2275309T3 (el)
PT (1) PT950096E (el)
WO (1) WO1999005263A1 (el)

Families Citing this family (48)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030144570A1 (en) * 1999-11-12 2003-07-31 Angiotech Pharmaceuticals, Inc. Compositions and methods for treating disease utilizing a combination of radioactive therapy and cell-cycle inhibitors
US7361643B2 (en) 2000-02-09 2008-04-22 University Of Puerto Rico Methods for inhibiting angiogenesis
AU2001243515A1 (en) * 2000-03-08 2001-09-17 Rhode Island Hospital, A Lifespan Partner Combination drug therapy
AU2001253479A1 (en) 2000-04-13 2001-10-30 Sts Biopolymers, Inc. Targeted therapeutic agent release devices and methods of making and using the same
AU2002223316A1 (en) * 2000-11-07 2002-05-21 University Of Victoria Innovation And Development Corporation Detection of proteases and screening for protease inhibitors
DE60207043T2 (de) 2001-02-05 2006-07-13 Innoventus Project Ab Histidin-reiches glykoprotein (hrgp) zur inhibierung der angiogenese
US6589997B2 (en) * 2001-06-29 2003-07-08 North Shore-Long Island Jewish Health System Small-molecule modulators of hepatocyte growth factor/scatter factor activities
CA2482856A1 (en) * 2002-04-15 2003-10-30 American National Red Cross Plasma protein-binding ligands
NZ540363A (en) * 2002-11-25 2007-11-30 Attenuon Llc Peptides which target tumor and endothelial cells, compositions and uses thereof
IL156566A0 (en) * 2003-06-19 2004-01-04 Hadasit Med Res Service Urokinase plasminogen activator derived octapeptide in the treatment of multiple sclerosis
WO2005002526A2 (en) * 2003-07-01 2005-01-13 President And Fellows Of Harvard College Method and compositions for treatment of viral infections
US7785632B2 (en) * 2003-09-15 2010-08-31 Ordway Research Institute, Inc. Thyroid hormone analogs and methods of use
US9198887B2 (en) 2003-09-15 2015-12-01 Nanopharmaceuticals Llc Thyroid hormone analogs and methods of use
US8668926B1 (en) 2003-09-15 2014-03-11 Shaker A. Mousa Nanoparticle and polymer formulations for thyroid hormone analogs, antagonists, and formulations thereof
US8071134B2 (en) * 2003-09-15 2011-12-06 Ordway Research Institute, Inc. Thyroid hormone analogs and methods of use
US20050101582A1 (en) 2003-11-12 2005-05-12 Allergan, Inc. Compositions and methods for treating a posterior segment of an eye
US7993634B2 (en) 2004-04-30 2011-08-09 Allergan, Inc. Oil-in-oil emulsified polymeric implants containing a hypotensive lipid and related methods
US9498457B2 (en) 2004-04-30 2016-11-22 Allergan, Inc. Hypotensive prostamide-containing biodegradable intraocular implants and related implants
US7799336B2 (en) 2004-04-30 2010-09-21 Allergan, Inc. Hypotensive lipid-containing biodegradable intraocular implants and related methods
US8722097B2 (en) 2004-04-30 2014-05-13 Allergan, Inc. Oil-in-water method for making polymeric implants containing a hypotensive lipid
TWI366459B (en) * 2004-09-28 2012-06-21 Ind Tech Res Inst Novel hydrophilic analogs of 4,8-dihydrobenzodithiophene-4,8-diones as anticancer agents
US10130686B2 (en) 2005-09-15 2018-11-20 Nanopharmaceuticals Llc Method and composition of thyroid hormone analogues and nanoformulations thereof for treating inflammatory disorders
US9498536B2 (en) 2005-09-15 2016-11-22 Nanopharmaceuticals Llc Method and composition of thyroid hormone analogues and nanoformulations thereof for treating anti-inflammatory disorders
US20100209382A1 (en) 2005-09-16 2010-08-19 Ordway Research Institute, Inc. Polyphenol Conjugates as RGD-Binding Compounds and Methods of Use
US20070134739A1 (en) * 2005-12-12 2007-06-14 Gyros Patent Ab Microfluidic assays and microfluidic devices
US8524663B2 (en) * 2006-03-03 2013-09-03 New York University Method for site-specific polyvalent display on polymers
EP1840570A1 (en) * 2006-03-31 2007-10-03 F. Hoffmann-La Roche Ag Tumor models employing green fluorescent protein
US8039010B2 (en) 2006-11-03 2011-10-18 Allergan, Inc. Sustained release intraocular drug delivery systems comprising a water soluble therapeutic agent and a release modifier
US8969415B2 (en) 2006-12-01 2015-03-03 Allergan, Inc. Intraocular drug delivery systems
ES2535005T3 (es) * 2006-12-22 2015-05-04 Nanopharmaceuticals Llc Formulaciones de nanopartículas y de polímeros para análogos, antagonistas y formulaciones de la hormona tiroidea, y usos de los mismos
US8481273B2 (en) * 2008-06-20 2013-07-09 University Of Delaware Perlecan fragments as biomarkers of bone stromal lysis
WO2010075332A1 (en) * 2008-12-23 2010-07-01 Charitable Leadership Foundation Small molecule ligands of the integrin rgd recognition site and methods of use
WO2010102253A2 (en) * 2009-03-06 2010-09-10 Angstrom Pharmaceuticals, Inc. Compositions and methods for modulation of cell migration
US9180107B2 (en) * 2009-03-31 2015-11-10 Nanopharmaceuticals Llc Combination treatment of cancer with cetuximab and tetrac
EP2442800B1 (en) 2009-06-17 2019-04-24 NanoPharmaceuticals LLC Nanoparticle and polymer formulations for thyroid hormone, analogs, antagonists, and formulations and uses thereof
ES2561083T3 (es) 2010-01-22 2016-02-24 Allergan, Inc. Implantes intracamerales de agentes terapéuticos de liberación sostenida
EP2542253A4 (en) * 2010-03-05 2013-08-21 Angstrom Pharmaceuticals Inc MODULATION OF AN INTERCELLULAR SIGNALING
US8802240B2 (en) 2011-01-06 2014-08-12 Nanopharmaceuticals Llc Uses of formulations of thyroid hormone analogs and nanoparticulate forms thereof to increase chemosensitivity and radiosensitivity in tumor or cancer cells
US10060934B2 (en) 2013-11-18 2018-08-28 Nanopharmaceuticals Llc Methods for screening patients for resistance to angioinhibition, treatment and prophylaxis thereof
EP3411058B1 (en) 2016-02-02 2023-03-08 Splash Pharmaceuticals, Inc. Combination therapy with a6 and paclitaxel for the treatment of ovarian cancer
WO2017214299A1 (en) 2016-06-07 2017-12-14 Nanopharmaceuticals, Llc NON-CLEAVABLE POLYMER CONJUGATED WITH αvβ3 INTEGRIN THYROID ANTAGONISTS
CN107722115A (zh) * 2017-11-29 2018-02-23 吉林大学 一种新型重组蜂毒多肽及其制备方法和应用
US11351137B2 (en) 2018-04-11 2022-06-07 Nanopharmaceuticals Llc Composition and method for dual targeting in treatment of neuroendocrine tumors
US10328043B1 (en) 2018-04-11 2019-06-25 Nanopharmaceuticals, Llc. Composition and method for dual targeting in treatment of neuroendocrine tumors
CN109180822B (zh) * 2018-11-14 2021-08-10 上海交通大学 一种猪链球菌b细胞优势表位串联疫苗及其制备方法
CN111603567A (zh) 2019-02-22 2020-09-01 博瑞生物医药（苏州）股份有限公司 Cd44靶向多臂偶联物
US10961204B1 (en) 2020-04-29 2021-03-30 Nanopharmaceuticals Llc Composition of scalable thyrointegrin antagonists with improved blood brain barrier penetration and retention into brain tumors
US11723888B2 (en) 2021-12-09 2023-08-15 Nanopharmaceuticals Llc Polymer conjugated thyrointegrin antagonists

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5422090A (en) 1984-08-13 1995-06-06 Biotechnology Australia, Pty., Ltd. Human PAI-2
IL81879A (en) 1986-03-13 1994-07-31 Biotech Australia Pty Ltd Purification of minactivin for homogeneity, production of minactivin as recombinant techniques, and uses of homogeneous or recombinant minactivin
US5073626A (en) 1988-11-09 1991-12-17 Monsanto Company Affinity purification of plasminogen activator inhibitor I using a modified urokinase
EP0467932B1 (en) 1989-04-07 2000-10-18 Cancerforskningsfonden af 1989 (fonden til fremme af eksperimentel cancerforskning) Urokinase-type plasminogen activator receptor
DK182289D0 (da) * 1989-04-14 1989-04-14 Francesco Blasi Modifikation af proteiner
WO1991002057A1 (en) 1989-08-09 1991-02-21 Delta Biotechnology Limited Polypeptide production in fungi
GB8919803D0 (en) 1989-09-01 1989-10-18 Ciba Geigy Pharmaceutical compositions
JP2567536B2 (ja) 1989-12-20 1996-12-25 バイオテック オーストラリア プロプライアタリィ リミティド Ｐａｉー２の変異体
GB2246779B (en) 1990-08-03 1994-08-17 Delta Biotechnology Ltd Tumour-associated protease inhibitors targeted to tumour cells
US5470970A (en) 1991-02-28 1995-11-28 Dana-Farber Cancer Institute, Inc. Maspin, a serpin with tumor suppresing activity
US5382514A (en) * 1992-03-31 1995-01-17 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services In vivo angiogenesis assay
DE69328092T2 (de) 1992-05-28 2000-07-20 Univ Toledo Bereitstellung einer für krebszellen cytotoxischen verbindung unter verwendung des weges von plasminogenaktivatormaterial
EP0673384A4 (en) * 1992-12-10 1996-10-09 Univ Minnesota POLYPEPTIDES USEFUL IN TREATING INFLAMMABLE DISEASES.
AU682877B2 (en) * 1993-05-28 1997-10-23 Chiron Corporation Peptide inhibitors of urokinase receptor activity
KR960702522A (ko) 1993-06-01 1996-04-27 로버트 피. 블랙버언 우로키나제 플라스미노겐 활성인자 억제인자의 발현(expression of urokinase plasminogen activator inhibitors)
DK85193D0 (da) 1993-07-16 1993-07-16 Cancerforskningsfondet Af 1989 Suppression of inhibitors
IT1271684B (it) 1994-07-22 1997-06-04 Consiglio Nazionale Ricerche Oligonucleotidi antisenso complementari all'rna messaggero del recettore umano della urochinasi
EP0842281A1 (en) * 1995-07-31 1998-05-20 Chiron Corporation Peptide analog inhibitors of urokinase receptor activity
US6509445B1 (en) * 1996-01-08 2003-01-21 Nissin Food Products Co., Ltd. Cancerous metastasis inhibitor

Also Published As

Publication number Publication date
DK0950096T3 (da) 2007-02-19
DE69836199T2 (de) 2007-09-13
US20110065640A1 (en) 2011-03-17
PT950096E (pt) 2007-02-28
ATE342967T1 (de) 2006-11-15
EP0950096A1 (en) 1999-10-20
EP0950096B1 (en) 2006-10-18
ES2275309T3 (es) 2007-06-01
CA2269772A1 (en) 1999-02-04
DE69836199D1 (de) 2006-11-30
US6696416B1 (en) 2004-02-24
US8110543B2 (en) 2012-02-07
US20030027768A1 (en) 2003-02-06
AU752205B2 (en) 2002-09-12
AU8590098A (en) 1999-02-16
US20090143303A1 (en) 2009-06-04
WO1999005263A1 (en) 1999-02-04
US7807621B2 (en) 2010-10-05
US5994309A (en) 1999-11-30

Similar Documents

Publication Publication Date Title
CY1107051T1 (el) Αντι-διηθητικα και αντι-αγγειογενετικα θραυσματα ουροκινασης και η χρηση τους
MA26458A1 (fr) Nouveaux derives cyclosporine, leur preparation et les compositions pharmaceutiques qui les contiennent.
HU213098B (en) Process for producing decapeptides antagonistic to hormone for releazing lutheinizing-hormone and pharmaceutical compositions containing them as active components
RU98123834A (ru) СПОСОБЫ И КОМПОЗИЦИИ, ИСПОЛЬЗУЕМЫЕ ДЛЯ ИНГИБИРОВАНИЯ αvβ5ОПОСРЕДОВАННОГО АНГИОГЕНЕЗА
JP5372096B2 (ja) 新規な抗腫瘍化合物
WO2004020462A1 (ja) Ｃｘｃｒ４拮抗薬およびその用途
EP0683173B1 (de) Cyclische Adhäsioninhibitoren
BRPI0721259A2 (pt) composto, composiÇço farmacÊutica, uso de composto, e, processo para a fabricaÇço de composto
ES2187958T3 (es) Antagonistas de gnrh.
KR920004418A (ko) 브래디키닌 길항제
JP2000512277A (ja) ペプチド誘導体
US5502035A (en) N-terminus modified analogs of LHRH
KR20000005210A (ko) 고리형 부착 억제제_
EP1363945B1 (en) Modified derivatives of cck-8
HUT77979A (hu) Peptidek, előállításuk és ezeket tartalmazó gyógyszerkészítmények
JPH08510260A (ja) Ｌｈｒｈ拮抗剤
EP0683792B1 (en) Lhrh antagonists having modified aminoacyl residues at postions 5 and 6
KR100555604B1 (ko) 탁산과 조합된 돌라스태틴-15 유도체
EP0219258A2 (en) Peptide antagonists of Neurokinin B and opthalmic solutions containing them
JP4800194B2 (ja) 乾癬の治療薬を製造するためのカハラリド化合物の使用
ES2291372T3 (es) Agonistas y antagonistas de urotensina-ii.
EP0738154A1 (en) N-terminus modified analogs of lhrh
DE10325049A1 (de) Peptid- und Peptidmimetika-Derivate mit Integrin-Inhibitor-Eigenschaften III
WO2007095659A1 (de) Peptide und peptid-derivate, herstellun derselben sowie deren verwendung zur herstellung eines therapeutisch und/oder präventiv wirkenden arzneimittels
DE19534016A1 (de) Biotinderivate